Literature DB >> 32166725

Amiodarone: A Comprehensive Guide for Clinicians.

David Hamilton1, Shuktika Nandkeolyar2, Howard Lan3, Pooja Desai4, Jonathan Evans5, Christopher Hauschild6, Dimpa Choksi7, Islam Abudayyeh3, Tahmeed Contractor3, Anthony Hilliard3.   

Abstract

Amiodarone is an effective antiarrhythmic medication frequently used in practice for both ventricular and atrial arrhythmias. Though classified as a class III antiarrhythmic, it affects all phases of the cardiac action potential. However, the drug has several side effects, including thyroid abnormalities, pulmonary fibrosis, and transaminitis, for which routine monitoring is recommended. It also interacts with several medications, such as warfarin, simvastatin, and atorvastatin, and many HIV antiretroviral medications. Given the common use of this medication in medical practice, it is vital that clinicians understand the indications, contraindications, dosing, side effects, and interactions of this medication. A thorough understanding of these topics is essential for clinicians to ensure safe and effective use of amiodarone.

Entities:  

Year:  2020        PMID: 32166725     DOI: 10.1007/s40256-020-00401-5

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.571


  9 in total

1.  Marked Increase of Gamma-Glutamyltransferase as an Indicator of Drug-Induced Liver Injury in Patients without Conventional Diagnostic Criteria of Acute Liver Injury.

Authors:  Sabine Weber; Julian Allgeier; Gerald Denk; Alexander L Gerbes
Journal:  Visc Med       Date:  2021-11-03

2.  When cardiology meets endocrinology: sustained atrial flutter associated with thyrotoxic periodic paralysis.

Authors:  Alejandro Sanchez-Nadales; Valentina Celis-Barreto; Alejandra Diaz-Sierra; Andres Sanchez-Nadales; Antonio Lewis; Jose Sleiman
Journal:  Oxf Med Case Reports       Date:  2022-03-16

3.  CLInical Profile and Side Effects of chronic use of oral Amiodarone in cardiology outpatients department (CLIPSE-A Study)- A prospective observational study.

Authors:  Nabeela Fatima; Kiranmai Mandava; Fatima Khatoon; Juveria Badar; Syeda Fatima Begum; C Narasimhan; K Daljeet; Walli Mohammed
Journal:  Ann Med Surg (Lond)       Date:  2022-07-16

4.  Protective Role of Amiodarone on Reperfusion Arrhythmia in Patients of Acute Myocardial Infarction with Percutaneous Coronary Intervention Treatment.

Authors:  Jianying Wang; Jinchang Leng; Xiaowei Sun; Kun Peng; Xaojuan Ma; Shiqin Huang; Fang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-26       Impact factor: 2.650

Review 5.  Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.

Authors:  Thiago Dominguez Crespo Hirata; Carolina Dagli-Hernandez; Fabiana Dalla Vecchia Genvigir; Volker Martin Lauschke; Yitian Zhou; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Mol Diagn Ther       Date:  2021-08-06       Impact factor: 4.074

Review 6.  Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials.

Authors:  Rami A Al-Horani; Srabani Kar; Kholoud F Aliter
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

7.  Low dose amiodarone reduces tumor growth and angiogenesis.

Authors:  Eliana Steinberg; Arnon Fluksman; Chalom Zemmour; Katerina Tischenko; Adi Karsch-Bluman; Yifat Brill-Karniely; Amy E Birsner; Robert J D'Amato; Ofra Benny
Journal:  Sci Rep       Date:  2020-10-22       Impact factor: 4.379

8.  Polypharmacy Is Associated With Amiodarone-Induced Hypothyroidism.

Authors:  Satoshi Yokoyama; Yuki Tanaka; Kouichi Hosomi; Mitsutaka Takada
Journal:  Int J Med Sci       Date:  2021-08-27       Impact factor: 3.738

9.  Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?

Authors:  Fabian Sanchis-Gomar; Carl J Lavie; Daniel P Morin; Carme Perez-Quilis; Jari A Laukkanen; Marco V Perez
Journal:  Am J Cardiovasc Drugs       Date:  2020-10       Impact factor: 3.283

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.